
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) – Equities researchers at HC Wainwright increased their Q4 2026 earnings per share (EPS) estimates for shares of Lakewood-Amedex Biotherapeutics in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($0.21) per share for the quarter, up from their previous estimate of ($1.44). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is $4.96 per share. HC Wainwright also issued estimates for Lakewood-Amedex Biotherapeutics’ FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.92) EPS.
Several other analysts have also recently issued reports on LABT. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lakewood-Amedex Biotherapeutics has an average rating of “Hold”.
Get Our Latest Report on Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics Price Performance
NASDAQ LABT opened at $0.24 on Thursday. The company has a market cap of $568,800.00 and a P/E ratio of -0.05. The stock has a 50-day moving average of $0.88 and a two-hundred day moving average of $5.20. Lakewood-Amedex Biotherapeutics has a 1-year low of $0.17 and a 1-year high of $98.20.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10).
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Recommended Stories
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
